Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Section 5 of 6

Economic information and modeling report

10 evidence topics · 9 sources

Modeling overview

Summary

No cost-effectiveness or budget impact model of claseprubart has been published. The ICER evaluation, taking a health system perspective over a 2-year time horizon, estimated $5,210,000 per QALY/evLYG for eculizumab and $2,076,000 per QALY/evLYG for efgartigimod at a placeholder price, and the ratio was never less than $3.8 million per QALY/evLYG for eculizumab or $1.7 million per QALY/evLYG for efgartigimod when model inputs were changed. A Markov model with a lifetime horizon estimated $3,338,000 per QALY gained for eculizumab and $1,987,000 per QALY gained for efgartigimod. A 2026 network meta-analysis using 2026 US costs found efgartigimod IV had the lowest cost per improved outcome among six approved biologics. In Canada, efgartigimod dominated chronic immunoglobulin over a lifetime horizon, and in the United Kingdom thymectomy plus prednisolone dominated prednisolone alone. A study that included 31 articles reported considerable variability in the costs and cost-effectiveness of myasthenia gravis treatments across regions, therapies, and health care settings. The company's market assumption is an average biologic net price of approximately $400,000 per patient per year.

Lifetime U.S. cost-effectiveness of eculizumab and efgartigimod in AChR antibody-positive gMG

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.